Effects of a HLA-B∗15:02 screening policy on antiepileptic drug use and severe skin reactions

Neurology

Volumn 83, Issue 22, 2014, Pages 2077-2084

  Chen, Zhibin ^a,b   Liew, Danny ^a,b   Kwan, Patrick ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; HARKOSERIDE; HLA B15 02 ANTIGEN; HLA B15 ANTIGEN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RUFINAMIDE; STIRIPENTOL; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; HLA-B*15:02 ANTIGEN;

ADOLESCENT; ADULT; AGED; ANTICONVULSANT THERAPY; ANXIETY DISORDER; ARTICLE; CHILD; CLINICAL PRACTICE; CONTROLLED STUDY; EPILEPSY; FEMALE; GENE FREQUENCY; GENETIC SCREENING; HEALTH CARE POLICY; HETEROZYGOTE; HONG KONG; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NEUROPATHIC PAIN; NEWBORN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HOSPITAL; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TURNAROUND TIME; CHEMICALLY INDUCED; CLINICAL TRIAL; EXANTHEMA; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PRESCHOOL CHILD; PROCEDURES; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; EXANTHEMA; FEMALE; GENETIC TESTING; HLA-B15 ANTIGEN; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84922479874     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001034     Document Type: Article

References (37)

1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-1285.
2. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study. J Invest Dermatol 2008; 128: 35-44.
3. Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B∗1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2013; 149: 1025-1032.
4. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.
5. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297-306.
6. Man CB, Kwan P, Baum L, et al. Association between HLAB∗1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48: 1015-1018.
7. Chang CC, Too CL, Murad S, Hussein SH. Association of HLA-B∗1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol 2011; 50: 221-224.
8. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B∗1502 allele in Thai population. Epilepsia 2008; 49: 2087-2091.
9. US Food and Drug Administration. Information for healthcare professionals: dangerous or even fatal skin reactions-carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics) [online]. Available at: http://www.fda. gov/Drugs/DrugSafety/Postmarketdrugsafetyinformationfor PatientsandProviders/ucm124718.htm. Accessed May 11, 2013.
10. UK Medicines and Healthcare Products Regulatory Agency. Carbamazepine: genetic testing recommended in some Asian populations [online]. Available at: http://www.mhra.gov.uk/Safetyinformation/DrugSafety Update/CON084888. Accessed October 17, 2013.
11. Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 2013; 94: 324-328.
12. Amstutz U, Shear NH, Rieder MJ, et al. Recommendations for HLA-B∗15: 02 and HLA-A∗31: 01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014; 55: 496-506.
13. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B∗1502 screening in Taiwan. N Engl J Med 2011; 364: 1126-1133.
14. Dong D, Sung C, Finkelstein EA. Cost-effectiveness of HLAB∗1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 2012; 79: 1259-1267.
15. Locharernkul C, Shotelersuk V, Hirankarn N. HLA-B∗1502 screening: time to clinical practice. Epilepsia 2010; 51: 936-938.
16. Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N, Mahasirimongkol S, Teerawattananon Y. Economic evaluation of HLA-B∗15: 02 screening for carbamazepineinduced severe adverse drug reactions in Thailand. Epilepsia 2013; 54: 1628-1638.
17. Census and Statistics Department, Hong Kong Special Administrative Region. 2011 Population Census. Thematic Report: Ethnic Minorities [online]. Available at: http://www.census2011.gov.hk/pdf/EM.pdf. Accessed May 11, 2013.
18. Hong Kong Hospital Authority. Hospital Authority Annual Report 2011-2012 [online]. Available at: http://www.ha.org.hk/upload/publication-13/435.pdf. Accessed October 10, 2013.
19. Hong Kong Special Administrative Region Government. Hong Kong: The Facts-Public Health. Hong Kong: Information Services Department, Hong Kong Special Administrative Region Government; 2012.
20. Ng M, Ng H. Re: genetic testing prior to prescription of carbamazepine [online]. Available at: http://www.cuhk. edu.hk/med/paf/ups/HLA-B-1502.pdf. Accessed May 11, 2013.
21. Cheung NT, Fung V, Kong JH. The Hong Kong Hospital Authority's information architecture. Stud Health Technol Inform 2004; 107: 1183-1186.
22. Cheung NT, Fung V, Chow YY, Tung Y. Structured data entry of clinical information for documentation and data collection. Stud Health Technol Inform 2001; 84: 609-613.
23. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-1607.
24. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27: 299-309.
25. Cochrane D, Orcutt GH. Application of least squares regression to relationships containing autocorrelated error terms. J Am Stat Assoc 1949; 44: 32-61.
26. Middleton D, Hawkins BR, Williams F, et al. HLA class I allele distribution of a Hong Kong Chinese population based on high-resolution PCR-SSOP typing. Tissue Antigens 2004; 63: 555-561.
27. Kwan P. What is the standard approach to assessment of an unprovoked seizure in an adult? Hong Kong. Neurol Clin Pract 2012; 2: 299-300.
28. Cheung YK, Cheng SH, Chan EJ, Lo SV, Ng MH, Kwan P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 2013; 54: 1307-1314.
29. Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010; 11: 349-356.
30. US Food and Drug Administration. Information for healthcare professionals: phenytoin (marketed as Dilantin, Phenytek and generics) and fosphenytoin sodium (marketed as Cerebyx and generics) [online]. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand Providers/ucm124788.htm. Accessed May 30, 2013.
31. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011; 10: 609-617.
32. Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-ofconcept trial. Lancet 2012; 379: 1705-1711.
33. UK National Institute for Health and Care Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care [online]. Available at: http://publications.nice.org. uk/the-epilepsies-the-diagnosis-and-management-of-theepilepsies- in-adults-and-children-in-primary-and-cg137. Accessed August 27, 2013.
34. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013; 54: 551-563.
35. Leung H, Man CY, Hui AC, Wong KS, Kwan P. Agreement between initial and final diagnosis of first seizures, epilepsy and non-epileptic events: a prospective study. J Neurol Neurosurg Psychiatry 2008; 79: 1144-1147.
36. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A∗3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 1134-1143.
37. Genin E, Chen DP, Hung SI, et al. HLA-A∗31: 01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J 2014; 14: 281-288.